Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more
Kezar Life Sciences Inc (KZR) - Total Assets
Latest total assets as of September 2025: $97.73 Million USD
Based on the latest financial reports, Kezar Life Sciences Inc (KZR) holds total assets worth $97.73 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kezar Life Sciences Inc - Total Assets Trend (2016–2024)
This chart illustrates how Kezar Life Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kezar Life Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Kezar Life Sciences Inc's total assets of $97.73 Million consist of 95.0% current assets and 5.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.9% |
| Accounts Receivable | $424.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Kezar Life Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kezar Life Sciences Inc's current assets represent 95.0% of total assets in 2024, an increase from 91.8% in 2016.
- Cash Position: Cash and equivalents constituted 28.9% of total assets in 2024, down from 85.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Kezar Life Sciences Inc Competitors by Total Assets
Key competitors of Kezar Life Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Kezar Life Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kezar Life Sciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kezar Life Sciences Inc is currently not profitable relative to its asset base.
Kezar Life Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.06 | 7.65 | 22.48 |
| Quick Ratio | 7.06 | 7.65 | 22.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $81.12 Million | $ 135.95 Million | $ 138.37 Million |
Kezar Life Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Kezar Life Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | -34.6% |
| Total Assets | $144.68 Million |
| Market Capitalization | $35.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kezar Life Sciences Inc's assets below their book value (0.24 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kezar Life Sciences Inc's assets decreased by 34.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kezar Life Sciences Inc (2016–2024)
The table below shows the annual total assets of Kezar Life Sciences Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $144.68 Million | -34.60% |
| 2023-12-31 | $221.24 Million | -26.15% |
| 2022-12-31 | $299.57 Million | +37.46% |
| 2021-12-31 | $217.93 Million | +43.53% |
| 2020-12-31 | $151.84 Million | +69.63% |
| 2019-12-31 | $89.51 Million | -21.95% |
| 2018-12-31 | $114.68 Million | +111.50% |
| 2017-12-31 | $54.22 Million | +374.63% |
| 2016-12-31 | $11.42 Million | -- |